Top News: #MultipleSclerosis

Here are the top read news for #MultipleSclerosis: Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS: Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity: Read more     Obesity and multiple sclerosis: Is there a causal…

Top News: #DrugSafety

Here are the top read news for #DrugSafety: By Sharing Painkillers, Friends and Family Members Can Fuel Opioid Epidemic: Study: It is not news that most people who use prescription painkillers for nonmedical reasons often get them through social channels rather than a physician. In 2013 — the most recent year for which this data…

Top News: #Biologics

Here are the top read news for #biologics:   Panel Defines Opportunistic Infections Tied to Biologics: An international consensus committee has defined the types and presentations of infectious pathogens that could be considered opportunistic infections (OI) within the setting of biologic therapy. Read more   Managing and Preventing Loss of Response to Biologics: Although biologics have…

Top News: #Biologics

Here are the top read news for #biologics: Not All Biologics Equally Safe for Patients With Psoriasis: A report of results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) suggests that treatment with adalimumab and infliximab are associated with a higher risk for serious infections than nonmethotrexate and nonbiologic therapies. The registry found no increased…